A provider briefing on Rifaximin (Xifaxan) availability in 2026: supply timeline, prescribing implications, cost barriers, and tools to help patients.
If your patients have been reporting difficulty filling Rifaximin (Xifaxan) prescriptions, their experience is consistent with a nationwide pattern. While Rifaximin is not listed on the FDA's official drug shortage database, intermittent stock-outs at retail pharmacies have become a persistent issue since 2023 — and the situation remains largely unchanged heading into 2026.
This briefing provides prescribers with an up-to-date overview of the supply landscape, prescribing implications, cost and access barriers, and practical tools to support patient access.
Rifaximin availability issues have evolved gradually rather than emerging from a single supply disruption:
The core issue is structural: single-source brand manufacturing combined with a medication that many pharmacies under-stock due to its high acquisition cost.
From a clinical standpoint, there are several considerations when prescribing Rifaximin in the current environment:
Patients may need 1 to 3 days for their pharmacy to order Rifaximin from the wholesaler. For patients on chronic Rifaximin therapy for hepatic encephalopathy, consider authorizing refills 5 to 7 days before the expected run-out date to build in a buffer.
Most commercial and Medicare plans place Rifaximin on Tier 3 or specialty tier, requiring prior authorization. Many plans also mandate step therapy — typically requiring a trial of Lactulose before approving Rifaximin for hepatic encephalopathy. Be prepared to submit clinical documentation supporting medical necessity, particularly for patients with documented Lactulose intolerance or treatment failure.
Rifaximin's use for SIBO remains off-label. Insurance coverage for off-label use varies significantly. When prescribing for SIBO, document the clinical rationale thoroughly, as many denials can be overturned on appeal with appropriate supporting evidence (e.g., positive breath test results, symptom documentation).
The availability situation varies by pharmacy type and geography:
Medfinder for Providers offers real-time pharmacy availability data that can help your practice direct patients to pharmacies with current stock.
Cost remains the single largest barrier to Rifaximin access for patients:
For a patient-facing resource on cost savings, direct patients to: How to Save Money on Rifaximin in 2026.
Several resources can help your practice support patients navigating Rifaximin access challenges:
The Rifaximin supply situation is unlikely to change substantially before 2029, when the first generic formulations may enter the US market. Until then:
Providers who build Rifaximin access planning into their workflow — including early refill authorization, PA preparedness, and patient education on pharmacy options — will be best positioned to keep their patients on therapy.
Rifaximin remains a cornerstone of treatment for hepatic encephalopathy and IBS-D, and its role in SIBO management continues to expand. The current supply challenges are driven by structural factors (single-source manufacturing, patent protection through 2029, high acquisition cost) rather than a traditional manufacturing shortage.
By leveraging tools like Medfinder for Providers, proactively managing prior authorizations, and connecting patients with cost-reduction programs, prescribers can mitigate the impact of these challenges and help ensure treatment continuity for their patients.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
